Anti-obesity medications differ in who they are approved for, the evidence behind their benefits, their risks, and how they fit into daily life. In the United States, clinicians generally consider medication alongside lifestyle support for adults with obesity or overweight plus a weight-related complication—but meeting a general BMI threshold does not guarantee eligibility for a particular drug, insurance coverage, or approval in another country.
Who may qualify for anti-obesity medication?
US guidance generally considers weight-management medication as an adjunct to diet, physical activity, and behavioral support for adults with a BMI of at least 30, or at least 27 with a weight-related complication. These are general treatment thresholds, not a promise that every drug is appropriate or covered. Product labels can differ by age, medical history, and indication, and approvals vary by country.
The Endocrine Society describes pharmacotherapy as an adjunct to lifestyle intervention. The 2025 Canadian guideline addresses selecting and using medication long term, while the American College of Physicians’ 2026 living guideline covers nonpregnant adults in outpatient care and conditionally suggests semaglutide and tirzepatide among first-line options for the groups it addresses. The ACP recommends discussing benefits, harms, cost, access, availability, comorbidities, weight-loss goals, life expectancy, values, preferences, contraindications, and warnings when starting or switching treatment.
A clinician can assess whether your health history and goals match a drug’s particular label. Adolescents are included in some US indications, but not all; the adult threshold should not be applied to younger people without age-specific clinical guidance.
Recommended Free Tools
#1 Best Overall
How do selected US options compare?
This comparison focuses on options with specific indication or trial information available here; it is not a complete list of weight-management drugs. Indications and warnings should be checked against the current US prescribing label, and may differ in other countries.
| Medicine | US population or use noted here | Evidence or decision points |
|---|---|---|
| Semaglutide (Wegovy) | The 2026 FDA label includes weight reduction and maintenance for specified adults and adolescents. It also includes cardiovascular risk reduction for adults with established cardiovascular disease and overweight or obesity, and an accelerated-approval MASH indication for a defined adult group. | In STEP 1, the mean weight change was −14.9% at 68 weeks in adults without diabetes. The label has a boxed warning about thyroid C-cell tumors observed in rodents; relevance to humans is unknown. It contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2. |
| Tirzepatide (Zepbound) | FDA’s adult chronic weight-management indication is for BMI at least 30, or at least 27 with one or more weight-related conditions, alongside a reduced-calorie diet and increased activity. | In SURMOUNT-1, mean weight change varied by studied dose over 72 weeks in adults without diabetes. FDA notes warnings that include pancreatitis, gallbladder problems, hypoglycemia, and acute kidney injury; consult the current label for full precautions. |
| Phentermine/topiramate ER (Qsymia) | The FDA label covers adults and pediatric patients aged 12 or older with obesity, and adults with overweight plus a weight-related comorbidity, alongside reduced-calorie eating and increased activity. | Contraindicated during pregnancy. For patients who can become pregnant, the label calls for a negative pregnancy test before treatment and monthly during treatment, plus specified laboratory monitoring. |
| Orlistat (alli, 60 mg) | FDA describes alli as an over-the-counter option for overweight adults aged 18 or older when used with its labeled reduced-calorie, low-fat diet. This OTC status does not apply to weight-loss medications generally. | FDA’s June 10, 2026 communication added advice about rare acute kidney injury and kidney stones, including for people with kidney disease or a history of stones. |
For Wegovy, FDA reported major adverse cardiovascular events in 6.5% of participants receiving the medicine and 8% receiving placebo. Those figures are from the FDA’s 2024 announcement about adults with cardiovascular disease and overweight or obesity, not a result that predicts an individual’s outcome. See the FDA announcement on reducing serious cardiovascular risks.
What do the weight-loss trial results show—and not show?
The pivotal trial results below provide useful context for two medicines, but they are not a head-to-head comparison. The studies differed in duration and were conducted separately; their averages should not be used to promise an individual result or rank the medicines for every patient.
| Study and participants | Treatment and duration | Mean body-weight change |
|---|---|---|
| STEP 1 investigators, published in The New England Journal of Medicine in 2021: 1,961 adults without diabetes with BMI at least 30, or at least 27 with one or more weight-related coexisting conditions. | Once-weekly subcutaneous semaglutide 2.4 mg or placebo, both alongside lifestyle intervention, for 68 weeks. | Semaglutide: −14.9%; placebo: −2.4%. |
| SURMOUNT-1 investigators, published in The New England Journal of Medicine in 2022: 2,539 adults without diabetes with BMI at least 30, or at least 27 with one or more weight-related complications. | Weekly tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks; treatment included dose escalation. | Tirzepatide 5 mg: −15.0%; 10 mg: −19.5%; 15 mg: −20.9%; placebo: −3.1%. |
These are trial averages in defined study populations receiving lifestyle intervention, not a forecast for a particular patient. The figures also do not capture every outcome that may matter, such as cardiovascular risk reduction, treatment tolerability, contraindications, or the practical burden of using a medicine.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Which benefits, risks, and practical factors should shape a choice?
Match the indication and health history
Start with the condition a medicine is intended to treat and the population in its current label. For example, Wegovy’s label includes indications beyond weight management, while the options above have different age groups and restrictions. Share your full medical history and medication list with the prescriber; conditions, other medicines, and personal or family history can change whether an option is suitable.
Weigh medicine-specific safety issues
There is no single safety profile for “weight-loss medication.” Semaglutide and tirzepatide labels include boxed warnings about thyroid C-cell tumors seen in rodents, with unknown relevance to humans. Wegovy also carries gastrointestinal and acute kidney injury due to volume depletion warnings, among other precautions. FDA’s Zepbound approval announcement identifies pancreatitis, gallbladder problems, hypoglycemia, and acute kidney injury among its warnings; the current label is needed for the complete list and contraindications. Qsymia’s pregnancy contraindication and testing requirements are central to its use. Orlistat’s OTC availability does not remove its kidney-related warning.
Rank #4
FDA said on January 13, 2026, that it found no increased risk of suicidal thoughts or actions with GLP-1 receptor agonists and requested removal of the corresponding warning from relevant labels. Older articles may describe a warning that is no longer current; check the latest label for the specific product.
Consider route, dosing, and staying on treatment
Route and dosing frequency can affect fit, but exact schedules and titration differ by product and formulation. STEP 1 and SURMOUNT-1 studied weekly injections; do not assume a trial schedule is a personalized prescription. Ask the prescriber or pharmacist how a specific product is taken, how dose changes work, what to do if a dose is missed, and what follow-up or monitoring is needed. Do not change a dose based on another medicine’s schedule.
Include affordability, access, and personal priorities
The medicine with the largest average effect in a separate trial is not automatically the best match for an individual. Discuss likely benefits and harms, cost and coverage, local availability, route and dosing burden, treatment goals, and your preferences with a clinician. No single cost or coverage comparison applies to every plan or location, so verify coverage and out-of-pocket cost for the exact product before deciding.
Quick Recap
How can you prepare for a clinician discussion?
- Write down your treatment goals and what outcomes matter most to you.
- Bring your medical history, current medicines, allergies, and relevant family history, including thyroid cancer or endocrine conditions.
- Ask which products’ labels fit your age, BMI, complications, and health history—and whether any contraindications or interactions apply.
- Discuss expected benefits and possible harms, monitoring, route, dosing burden, and what follow-up would look like.
- Check the exact product’s coverage, out-of-pocket cost, and availability with your insurer and pharmacy.
- Use licensed clinical care and FDA-approved products. FDA has raised concerns about unapproved GLP-1 products, including product and provider quality, dosing, and titration; seek advice from a qualified clinician rather than relying on unapproved sources.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
